AR043003A1 - Compuestos (benzoimidazol-2-il) fenilaminas n-sustituidas, procedimiento para su preparacion, su uso como farmacos o como ayuda en diagnostico, y los medicamentos que las contienen - Google Patents

Compuestos (benzoimidazol-2-il) fenilaminas n-sustituidas, procedimiento para su preparacion, su uso como farmacos o como ayuda en diagnostico, y los medicamentos que las contienen

Info

Publication number
AR043003A1
AR043003A1 ARP040100315A ARP040100315A AR043003A1 AR 043003 A1 AR043003 A1 AR 043003A1 AR P040100315 A ARP040100315 A AR P040100315A AR P040100315 A ARP040100315 A AR P040100315A AR 043003 A1 AR043003 A1 AR 043003A1
Authority
AR
Argentina
Prior art keywords
atoms
substituted
alkyl
independently
alkoxy
Prior art date
Application number
ARP040100315A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR043003A1 publication Critical patent/AR043003A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a (benzoimidazol-2-il)fenilaminas N-sustituidas y los medicamentos que contienen compuestos de este tipo que son útiles en la prevención o tratamiento de varios trastornos, Así, los compuestos pueden emplearse inter alia para trastornos renales tales como insuficiencia aguda o crónica del rinón, trastornos de la función biliar, trastornos respiratorios tales como ronquidos o apneas del sueno o para el ictus. Reivindicación 1: Un compuesto de fórmula (1) en la que: R1 y R4 son independientemente H, F, Cl, Br, alquilo de 1,2,3, o 4 átomos de C o alcoxilo de 1,2,3,o 4átomos de C, en la que los grupos alquilo y alcoxilo no están sustituidos o están independientemente sustituidos con 1,2,3,4,5,6,7,8,o 9 átomos de F; R2 y R3 son independientemente H, F, alquilo de 1,2 o 3 átomos de C, alcoxilo de 1,2, o 3 átomos de C o OH, en la que los grupo alquilo y alcoxilo no están sustituidos o están independientemente sustituidos con 1,2,3,4,5,6 o 7 átomos de F; R5 es un grupo alquilo de 1,2,3,4 o 4 átomos de C, alquenilo de 2,3 o 4 átomos de C o cicloalquilo de 3,4, o5 átomos de C, en la que los grupos alquilo, alquenilo y cicloalquilo no están sustituidos o están sustituidos con 1,2,3,4,5,6,7,8 o.9 átomos de F; R6 y R7 son independientemente H, F, Cl, Br, alquilo de 1,2,3, o 4 átomos de C o alcoxilo de 1,2, o 3, átomos de C, en la que los grupos alquilo y alcoxilo no están sustituidos o están independientemente sustituidos con 1,2,3,4,5,6,7,8 o 9 átomos de F; y al menos uno de los dos radicales R6 o R7 no es H; y las sales farmacéuticamente aceptables y sus sales con ácido trifluoroacético.
ARP040100315A 2003-02-04 2004-02-02 Compuestos (benzoimidazol-2-il) fenilaminas n-sustituidas, procedimiento para su preparacion, su uso como farmacos o como ayuda en diagnostico, y los medicamentos que las contienen AR043003A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10304294A DE10304294A1 (de) 2003-02-04 2003-02-04 N-Substituierte(Benzoimidazol-2-yl)-phenyl, Verfahren zu ihrer Herstellung , ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
AR043003A1 true AR043003A1 (es) 2005-07-13

Family

ID=32695159

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100315A AR043003A1 (es) 2003-02-04 2004-02-02 Compuestos (benzoimidazol-2-il) fenilaminas n-sustituidas, procedimiento para su preparacion, su uso como farmacos o como ayuda en diagnostico, y los medicamentos que las contienen

Country Status (12)

Country Link
EP (1) EP1592671B1 (es)
JP (1) JP4630270B2 (es)
AR (1) AR043003A1 (es)
AT (1) ATE391714T1 (es)
AU (1) AU2004208871A1 (es)
BR (1) BRPI0407199A (es)
CA (1) CA2513821A1 (es)
DE (2) DE10304294A1 (es)
MX (1) MXPA05007247A (es)
PE (1) PE20041041A1 (es)
TW (1) TW200507837A (es)
WO (1) WO2004069811A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2612922A1 (en) 2005-06-21 2006-12-28 Neurosearch A/S 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
DK2271327T3 (en) * 2008-05-09 2015-07-13 Merck Patent Gmbh Pharmaceutical composition comprising rhymeporide for the treatment of diseases associated with beta-cell dysfunction
RU2703456C2 (ru) 2014-07-25 2019-10-17 Тайсо Фармасьютикал Ко., Лтд. Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом
US20260042743A1 (en) * 2022-08-01 2026-02-12 Council Of Scientific And Industrial Research Substituted benzimidazoles for treating viral diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR900100380A (el) * 1989-05-20 1991-10-10 Fisons Plc Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης.
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
EP0966465B1 (en) * 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
JPH10330369A (ja) * 1997-04-04 1998-12-15 Sumitomo Pharmaceut Co Ltd 複素環化合物
WO2001021160A2 (en) * 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
DE10060292A1 (de) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament

Also Published As

Publication number Publication date
PE20041041A1 (es) 2005-02-04
DE10304294A1 (de) 2004-08-12
TW200507837A (en) 2005-03-01
DE502004006770D1 (de) 2008-05-21
MXPA05007247A (es) 2005-09-08
CA2513821A1 (en) 2004-08-19
EP1592671A1 (de) 2005-11-09
JP4630270B2 (ja) 2011-02-09
EP1592671B1 (de) 2008-04-09
ATE391714T1 (de) 2008-04-15
BRPI0407199A (pt) 2006-02-14
JP2006516577A (ja) 2006-07-06
WO2004069811A1 (de) 2004-08-19
AU2004208871A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
ME02490B (me) Hemijska jedinjenja
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
AR063707A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
AR063706A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
RU2009125578A (ru) Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний
BR112012020557A8 (pt) formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
BR112013024059A2 (pt) compostos de bis(fluoroalquil)-1,4-benzodiazepinona
UY28374A1 (es) Agentes terapéuticos
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR064319A1 (es) Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
AR051431A1 (es) Compuestos de pirazolina substituidos, su preparacion y su uso como medicamentos
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
MY167396A (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
ECSP12011695A (es) Derivados de (tio) morfolina como moduladores de s1p
RU2014119711A (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
BRPI0519287A2 (pt) derivados de amida
RU2015150120A (ru) Соединение дикарбоновой кислоты
BRPI1016232A2 (pt) Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol
AR043741A1 (es) 4-feniltetrahidroisoquinoleinas sustituidas, su uso como un medicamento, y el medicamento que las comprende

Legal Events

Date Code Title Description
FB Suspension of granting procedure